In vitro hepatic metabolism of CYP3A-mediated drug, quinine in the Antarctic Adelie penguins

被引：0
|
作者：
Wanwimolruk, S [1 ]
Zhang, H [1 ]
Coville, PF [1 ]
Saville, DJ [1 ]
Davis, LS [1 ]
机构：
[1] Univ Otago, Sch Pharm, Dunedin, New Zealand
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 1998年 / 358卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P43
引用
收藏
页码：R416 / R416
页数：1
相关论文
共 50 条
  • [21] Drug Interaction of Efavirenz and Midazolam: Efavirenz Activates the CYP3A-Mediated Midazolam 1′-Hydroxylation In Vitro
    Keubler, Anja
    Weiss, Johanna
    Haefeli, Walter E.
    Mikus, Gerd
    Burhenne, Juergen
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (06) : 1178 - 1182
  • [22] Rabbit as an animal model to predict CYP3A-mediated drug-drug interactions
    Chauret, N
    Sleno, L
    Silva, J
    Houle, R
    Day, S
    Nicoll-Griffith, DA
    CYTOCHROMES P450, BIOCHEMISTRY, BIOPHYSICS AND DRUG METABOLISM, 2003, : 157 - 162
  • [23] Effects of Danshen and its tanshinone components on CYP3A-mediated metabolism of testosterone in rat and human liver in vitro
    Wang, Xin
    Yeung, H. K. John
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 208 - 208
  • [24] A novel testosterone 6β-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro
    Fayer, JL
    Petullo, DM
    Ring, BJ
    Wrighton, SA
    Ruterbories, KJ
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2001, 46 (02) : 117 - 123
  • [25] Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
    Janneke M. Brussee
    Huixin Yu
    Elke H. J. Krekels
    Semra Palić
    Margreke J. E. Brill
    Jeffrey S. Barrett
    Amin Rostami-Hodjegan
    Saskia N. de Wildt
    Catherijne A. J. Knibbe
    Pharmaceutical Research, 2018, 35
  • [26] Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
    Brussee, Janneke M.
    Yu, Huixin
    Krekels, Elke H. J.
    Palic, Semra
    Brill, Margreke J. E.
    Barrett, Jeffrey S.
    Rostami-Hodjegan, Amin
    de Wildt, Saskia N.
    Knibbe, Catherijne A. J.
    PHARMACEUTICAL RESEARCH, 2018, 35 (09)
  • [27] The effect of tazemetostat on CYP3A-mediated metabolism of midazolam in patients with solid tumors
    Smith, Sherri
    Suttle, Benjamin
    Waters, Nigel L.
    Ribrag, Vincent
    Italiano, Antoine
    Michot, Jean-Marie
    Postel-Vinay, Sophie
    Toulmonde, Maud
    Cousin, Sophie
    Roche, Maria
    Pimentel, Patricia
    Ho, Peter
    CANCER RESEARCH, 2016, 76
  • [28] Evaluation of CYP3A-Mediated Drug-Drug Interactions With Romidepsin in Patients With Advanced Cancer
    Laille, Eric
    Patel, Manish
    Jones, Suzanne F.
    Burris, Howard A., III
    Infante, Jeffrey
    Lemech, Charlotte
    Liu, Liangang
    Arkenau, Hendrik-Tobias
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (12): : 1378 - 1385
  • [29] Proposal of a Safe and Effective Study Design for CYP3A-Mediated Drug-Drug Interactions
    Rohr, Brit Silja
    Mikus, Gerd
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (10): : 1294 - 1303
  • [30] In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: A preclinical approach for CYP3A-mediated drug interaction studies
    Prueksaritanont, Thomayant
    Kuo, Yuhsin
    Tang, Cuyue
    Li, Chunze
    Qiu, Yue
    Lu, Bing
    Strong-Basalyga, Kristie
    Richards, Karen
    Carr, Brian
    Lin, Jiunn H.
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (09) : 1546 - 1555
12345